Clinical Trials Logo

Neurofibromatosis Type 1 (NF1) clinical trials

View clinical trials related to Neurofibromatosis Type 1 (NF1).

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03962543 Active, not recruiting - Clinical trials for Plexiform Neurofibroma

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

ReNeu
Start date: September 29, 2019
Phase: Phase 2
Study type: Interventional

This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.